JP2016512514A - チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 - Google Patents

チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 Download PDF

Info

Publication number
JP2016512514A
JP2016512514A JP2016501053A JP2016501053A JP2016512514A JP 2016512514 A JP2016512514 A JP 2016512514A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016501053 A JP2016501053 A JP 2016501053A JP 2016512514 A JP2016512514 A JP 2016512514A
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
aromatic
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016501053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512514A5 (cg-RX-API-DMAC7.html
Inventor
ジョランタ グレンベッカ，
ジョランタ グレンベッカ，
トマス シエルピキ，
トマス シエルピキ，
ドミトリー ボルキン，
ドミトリー ボルキン，
ジェイ ヘス，
ジェイ ヘス，
ドゥシン スン，
ドゥシン スン，
シャオチン リー，
シャオチン リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2016512514A publication Critical patent/JP2016512514A/ja
Publication of JP2016512514A5 publication Critical patent/JP2016512514A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016501053A 2013-03-13 2014-03-10 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 Withdrawn JP2016512514A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088243A Division JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2016512514A true JP2016512514A (ja) 2016-04-28
JP2016512514A5 JP2016512514A5 (cg-RX-API-DMAC7.html) 2017-05-18

Family

ID=51529943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501053A Withdrawn JP2016512514A (ja) 2013-03-13 2014-03-10 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
JP2018088243A Active JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018088243A Active JP6670885B2 (ja) 2013-03-13 2018-05-01 チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法

Country Status (11)

Country Link
US (4) US9216993B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968342B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016512514A (cg-RX-API-DMAC7.html)
KR (1) KR20150130389A (cg-RX-API-DMAC7.html)
CN (1) CN105188705A (cg-RX-API-DMAC7.html)
AU (1) AU2014249233A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904612A1 (cg-RX-API-DMAC7.html)
IL (1) IL241193A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011576A (cg-RX-API-DMAC7.html)
WO (1) WO2014164543A1 (cg-RX-API-DMAC7.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤
WO2019189732A1 (ja) * 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
JP2019530745A (ja) * 2016-09-14 2019-10-24 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用の縮合二環式阻害剤
JP2019532100A (ja) * 2016-09-14 2019-11-07 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用のスピロ二環式阻害剤
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2021506882A (ja) * 2017-12-20 2021-02-22 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用のエキソ−アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP2025501287A (ja) * 2021-12-31 2025-01-17 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Ｍｅｎｉｎ阻害剤及びその用途
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323360B2 (en) * 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP4643952A2 (en) * 2016-01-26 2025-11-05 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
ES2947636T3 (es) * 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
MY199965A (en) 2016-03-16 2023-11-30 Univ Michigan Regents Bridged bicyclic inhibitors of menin-mll and methods of use
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
WO2018183857A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN112771055B (zh) * 2018-08-08 2023-10-20 住友制药株式会社 光学活性桥接哌啶衍生物
US20210353610A1 (en) 2018-10-03 2021-11-18 The Regents Of The University Of Michigan Small molecule menin inhibitors
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
SG11202104243VA (en) * 2018-12-06 2021-05-28 Daiichi Sankyo Co Ltd Cycloalkane-1,3-diamine derivative
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
US11572369B2 (en) * 2019-02-01 2023-02-07 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
SG11202113154YA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20230405008A1 (en) * 2020-10-21 2023-12-21 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
US20250333421A1 (en) 2021-06-03 2025-10-30 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503906A (ja) * 2009-09-04 2013-02-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) * 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
AU2009291783A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503906A (ja) * 2009-09-04 2013-02-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 120, no. 23, JPN6017045378, 2012, pages 4461 - 4469, ISSN: 0003689140 *
NATURE CHEMICAL BIOLOGY, vol. 8, no. 3, JPN6017045377, 2012, pages 277 - 284, ISSN: 0003689139 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7461390B2 (ja) 2016-06-10 2024-04-03 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
JP2024045176A (ja) * 2016-06-10 2024-04-02 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤
JP2022058514A (ja) * 2016-06-10 2022-04-12 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
JP7007302B2 (ja) 2016-06-10 2022-01-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン－ｍｌｌ相互作用の阻害剤
JP7033141B2 (ja) 2016-09-14 2022-03-09 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用の縮合二環式阻害剤
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP2019530745A (ja) * 2016-09-14 2019-10-24 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用の縮合二環式阻害剤
JP2019532100A (ja) * 2016-09-14 2019-11-07 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用のスピロ二環式阻害剤
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
JP7749608B2 (ja) 2017-03-24 2025-10-06 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP7628392B2 (ja) 2017-03-24 2025-02-10 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2023055735A (ja) * 2017-03-24 2023-04-18 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP2021506882A (ja) * 2017-12-20 2021-02-22 ヤンセン ファーマシューティカ エヌ．ベー． メニン−ｍｌｌ相互作用のエキソ−アザスピロ阻害剤
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
JPWO2019189732A1 (ja) * 2018-03-30 2021-04-08 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
CN112105621A (zh) * 2018-03-30 2020-12-18 大日本住友制药株式会社 光学活性桥型环状仲胺衍生物
WO2019189732A1 (ja) * 2018-03-30 2019-10-03 大日本住友製薬株式会社 光学活性な架橋型環状２級アミン誘導体
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
JP7707189B2 (ja) 2019-11-29 2025-07-14 大鵬薬品工業株式会社 Ｋｒａｓ ｇ１２ｄ変異に対して阻害活性を有する化合物
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
JP2025501287A (ja) * 2021-12-31 2025-01-17 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 Ｍｅｎｉｎ阻害剤及びその用途

Also Published As

Publication number Publication date
BR112015022602A2 (pt) 2017-07-18
US9505782B2 (en) 2016-11-29
US20160137665A1 (en) 2016-05-19
US9216993B2 (en) 2015-12-22
WO2014164543A1 (en) 2014-10-09
EP2968342A4 (en) 2016-07-27
EP2968342A1 (en) 2016-01-20
CN105188705A (zh) 2015-12-23
KR20150130389A (ko) 2015-11-23
JP2018115214A (ja) 2018-07-26
US20140275070A1 (en) 2014-09-18
US10160769B2 (en) 2018-12-25
IL241193A0 (en) 2015-11-30
US20170253611A1 (en) 2017-09-07
AU2014249233A1 (en) 2015-09-24
JP6670885B2 (ja) 2020-03-25
EP2968342B1 (en) 2018-10-03
US9505781B2 (en) 2016-11-29
CA2904612A1 (en) 2014-10-09
MX2015011576A (es) 2016-05-16
US20160046647A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
JP6670885B2 (ja) チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
CN113811300B (zh) Tead转录因子的新型小分子抑制剂
JP6759514B2 (ja) ブロモドメインに対して活性な化合物
ES2398606T3 (es) Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
ES2534227T3 (es) Derivados de 4-aminopirimidina y su uso como antagonistas del receptor A2A de adenosina
AU2020203464A1 (en) Sulfonylureas and related compounds and use of same
BR112020026748A2 (pt) Inibidores de quinases dependentes de ciclina
ES2351110T3 (es) Compuestos de piperidinilamino-tieno[2,3-d]-pirimidina.
JP4173191B2 (ja) Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体
RS63603B1 (sr) Sredstva za indukciju apoptoze
JP2008514643A (ja) 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物
AU2017327304B2 (en) Use of morphinan derivative for therapeutic treatment of opioid δ receptor agonist-related disease
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
CA2979758A1 (en) New fyn kinase inhibitors
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
KR20130005263A (ko) 치환된 나프탈레닐-피리미딘 화합물
AU2022345092A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
CN106986832A (zh) Vegfr3抑制剂
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN115279747B (zh) Fyn和vegfr2激酶抑制剂
WO2021000957A1 (zh) 一种杂环化合物、其药物组合物及用途
BR112017017610B1 (pt) Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180227

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180611